Afami-Cel Receives Accelerated Approval From the FDA for Advanced Synovial Sarcoma
Accelerated approval has been granted by the FDA to afamitresgene autoleucel for certain patients with pretreated unresectable or metastatic synovial sarcoma.
FDA Expands Approval of Dostarlimab for Advanced, Recurrent Endometrial Cancer
A dostarlimab-gxly combination was approved for advanced or recurrent endometrial cancer.
Subcutaneous Daratumumab Plus VRd Receives FDA Approval for Multiple Myeloma
Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT.
FDA Approves Shield Blood Test to Screen for CRC in Adults
The FDA approved the Shield blood test for colorectal screening in adults aged 45 years and older with an average risk for the disease.
FDA Grants Fast Track Designation to OBX-115 for Advanced Melanoma
The TIL cell therapy OBX-115 received fast track designation from the FDA for locally advanced or metastatic melanoma.
BNT324/DB-1311 Receives Fast Track Designation From FDA for mCRPC
The antibody drug conjugate BNT324/DB-1311 received fast track designation for the potential treatment of unresectable advanced or metastatic castration-resistant prostate cancer with disease progression.
FDA Grants Fast Track Status to Dendritic Cell Vaccine for Pancreatic Cancer
The fast track status from the FDA is supported by findings from a phase 1 trial in glioblastoma, which demonstrated the overall survival benefit from DOC1021.
DSP-5336 Receives Fast Track Designation From the FDA for Acute Myeloid Leukemia Subtype
The FDA granted the investigational menin-MLL inhibitor DSP-5336 fast track designation for KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.
FDA Grants Fast Track Designation to ADI-270 for Pretreated Advanced ccRCC
The CAR T-cell therapy ADI-270 received fast track designation from the FDA for pretreated advanced clear cell renal cell carcinoma.
Alpha-Emitting Radspherin Receives Fast Track Status for Peritoneal Carcinomatosis From Ovarian Cancer
Alpha-emitting radiopharmaceutical Radspherin receives a fast track designation from the FDA for peritoneal carcinomatosis from ovarian cancer.
Cosibelimab BLA Resubmitted for Locally Advanced, Metastatic CSCC
The resubmission of the biologics license application for cosibelimab for locally advanced or metastatic cutaneous squamous cell carcinoma follows a complete response letter from the FDA in December 2023.
FDA Updates REMS for CAR T-Cell Therapies for Hematologic Malignancies
The updated risk evaluation and mitigation strategies for autologous CAR T-cell therapy removed requirements for training and educational materials about the risk for certain toxicities.
Oncology Drugs Approved by the FDA in June 2024
Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma.
IBI343 Earns FDA Fast Track Status for Advanced/Metastatic PDAC
Monotherapy with IBI343 received fast track designation from the FDA for advanced unresectable or metastatic pancreatic ductal adenocarcinoma.
Pembrolizumab Plus Chemo Receives Priority Review From the FDA for Advanced Pleural Mesothelioma
An sBLA was granted priority review from the FDA, which is seeking the approval of pembrolizumab plus chemotherapy for the frontline treatment of malignant pleural mesothelioma.
FDA Approves Tepylute to Treat Breast, Ovarian Cancers
The ready-to-dilute formulation of Tepylute for breast and ovarian cancers can help to reduce prep time and provide more accurate dosing.
FDA Approves Epcoritamab for Relapsed/Refractory Follicular Lymphoma
An accelerated approval has been granted by the FDA to epcoritamab-bysp (Epkinly) for adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.
FDA Approves Adagrasib for KRAS G12C-Mutated Metastatic Colorectal Cancer
Accelerated approval has been granted to adagrasib for use with cetuximab in previously treated adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
FDA Receives BLA Seeking Approval for Subcutaneous Amivantamab in EGFR+ NSCLC
The biologics license application for subcutaneous amivantamab is seeking approval for the treatment of EGFR-positive non-small cell lung cancer.
FDA Approves Pembrolizumab Plus Chemo for Advanced or Recurrent Endometrial Cancer
The approval of this pembro-chemo combination for adults with primary advanced or recurrent endometrial carcinoma includes those with mismatch repair-proficient or -deficient disease.
FDA OKs Blinatumomab for Children, Adults with CD-19 B-ALL in Consolidation Phase
The FDA approved blinatumomab for patients 1 month or older with CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia.
FDA Approves Durvalumab-Chemo Regimen for Advanced or Recurrent dMMR Endometrial Cancer
The FDA approved durvalumab plus carboplatin and paclitaxel, followed by single-agent durvalumab for primary advanced or recurrent dMMR endometrial cancer.
FDA Approves Repotrectinib for NTRK Gene Fusion-Positive Solid Tumors
The FDA granted accelerated approval to repotrectinib to treat adult and pediatric patients with NTRK gene fusion-positive solid tumors.
FDA Grants Traditional Approval to Selpercatinib for Advanced/Metastatic RET Fusion-Positive Thyroid Cancer
This traditional approval updates the accelerated approval that selpercatinib received in 2020 for this indication in patients 12 years and older.
Osimertinib Receives Priority Review From the FDA for EGFR+ Stage III NSCLC
The priority review granted by the FDA to the supplemental new drug application for osimertinib is seeking approval for its treatment of stage III non-small cell lung cancer with EGFR mutations.
Imetelstat Gets FDA Approval for Low- to Intermediate-1-Risk MDS With Transfusion-Dependent Anemia
The FDA granted an approval to imetelstat for certain patients with low- to intermediate-1-risk MDS who have transfusion-dependent anemia.
FDA Approves Liso-Cel for Relapsed/Refractory Mantle Cell Lymphoma
This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.
FDA Approves Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer, Solid Tumors
Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid tumors with RET mutations.
Cervical Cancer Test Receives Breakthrough Device Designation from FDA
A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.
Approval of Infigratinib Withdrawn by the FDA for Advanced FGFR2+ Cholangiocarcinoma
The accelerated approval of infigratinib has been withdrawn by the FDA for previously treated, FGFR2-positive, advanced cholangiocarcinoma.
Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs